TrialsgrambetaRCTs are beautiful
ESC 2019 Pulmonary Embolism

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism

The 2019 ESC guideline makes direct oral anticoagulants the default in acute pulmonary embolism, formalises risk stratification by haemodynamics, right-ventricular function and biomarkers, and confines full-dose systemic fibrinolysis to high-risk disease and to rescue in deteriorating intermediate-risk patients. The register's anticoagulation and reperfusion trials are grouped below.

This guideline cites 5 of the 199 landmark trials in our Cardiology register.

Source
Konstantinides SV, Meyer G, et al. Eur Heart J. 2020;41(4):543–603. · European Heart Journal
Read the full guideline ↗

Anticoagulation — direct oral anticoagulants3

  • 2013HOKUSAI-VTECardiology · Thrombosis · Venous thromboembolismEdoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
  • 2013AMPLIFYCardiology · Thrombosis · Venous thromboembolismApixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis
  • 2012EINSTEIN-PECardiology · Thrombosis · Pulmonary embolismOral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

Reperfusion — systemic & catheter-directed2

  • 2014PEITHOCardiology · Thrombosis · Pulmonary embolismPulmonary Embolism Thrombolysis trial
  • 2014ULTIMACardiology · Thrombosis · Pulmonary embolismUltrasound Accelerated Thrombolysis of Pulmonary Embolism

Published since the guideline1

  • 2020CARAVAGGIOCardiology · Thrombosis · Venous thromboembolismApixaban for the Treatment of Venous Thromboembolism Associated with Cancer